Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet ...

Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...